The estimated Net Worth of Brian Piper is at least 41.7 千$ dollars as of 25 August 2021. Brian Piper owns over 8,333 units of Prelude Therapeutics Inc stock worth over 41,665$ and over the last 8 years Brian sold PRLD stock worth over 0$.
Brian has made over 2 trades of the Prelude Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Brian exercised 8,333 units of PRLD stock worth 15,749$ on 25 August 2021.
The largest trade Brian's ever made was exercising 8,333 units of Prelude Therapeutics Inc stock on 25 August 2021 worth over 15,749$. On average, Brian trades about 2,381 units every 13 days since 2017. As of 25 August 2021 Brian still owns at least 8,333 units of Prelude Therapeutics Inc stock.
You can see the complete history of Brian Piper stock trades at the bottom of the page.
Brian's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON, DE, 19803.
Over the last 5 years, insiders at Prelude Therapeutics Inc have traded over 822,895$ worth of Prelude Therapeutics Inc stock and bought 5,875,215 units worth 87,687,261$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、David P Bonita、Advisors Llc Orbi Med Capit.... On average, Prelude Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 608,735$. The most recent stock trade was executed by Jane Huang on 4 July 2024, trading 9,375 units of PRLD stock currently worth 46,875$.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Prelude Therapeutics Inc executives and other stock owners filed with the SEC include: